Rallybio Corporation

NasdaqGS:RLYB Stock Report

Market Cap: US$44.8m

Rallybio Management

Management criteria checks 2/4

Rallybio's CEO is Steve Uden, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $1.78M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 1.73% of the company’s shares, worth $776.66K. The average tenure of the management team and the board of directors is 5.8 years and 4.1 years respectively.

Key information

Steve Uden

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage29.8%
CEO tenure6.8yrs
CEO ownership1.7%
Management average tenure5.8yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Aug 28
We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Sep 19
Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

May 15
Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Jan 30
We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Oct 31
Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Jul 07
Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

Mar 16
Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

CEO Compensation Analysis

How has Steve Uden's remuneration changed compared to Rallybio's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$74m

Mar 31 2024n/an/a

-US$76m

Dec 31 2023US$2mUS$530k

-US$75m

Sep 30 2023n/an/a

-US$71m

Jun 30 2023n/an/a

-US$71m

Mar 31 2023n/an/a

-US$69m

Dec 31 2022US$1mUS$491k

-US$67m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$55m

Mar 31 2022n/an/a

-US$48m

Dec 31 2021US$3mUS$441k

-US$47m

Sep 30 2021n/an/a

-US$45m

Jun 30 2021n/an/a

-US$42m

Mar 31 2021n/an/a

-US$36m

Dec 31 2020US$838kUS$380k

-US$26m

Compensation vs Market: Steve's total compensation ($USD1.78M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.


CEO

Steve Uden (66 yo)

6.8yrs

Tenure

US$1,778,284

Compensation

Dr. Stephen Uden, also known as Steve, MD, is Chief Executive Officer and Director of Rallybio, LLC since August 01, 2023 and serves as its President. Dr. Uden is a Co-Founder of Rallybio, LLC in 2018 and...


Leadership Team

NamePositionTenureCompensationOwnership
Martin MacKay
Co-Founder & Executive Chairman6.8yrsUS$1.78m1.73%
$ 776.7k
Stephen Uden
Co-Founder6.8yrsUS$1.78m1.73%
$ 776.7k
Jonathan Lieber
CFO & Treasurer1.8yrsUS$1.91m0.012%
$ 5.4k
Steven Ryder
Chief Medical Officer5.8yrsUS$1.27m0.46%
$ 207.8k

5.8yrs

Average Tenure

67yo

Average Age

Experienced Management: RLYB's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Martin MacKay
Co-Founder & Executive Chairman6.8yrsUS$1.78m1.73%
$ 776.7k
Stephen Uden
Co-Founder1.3yrsUS$1.78m1.73%
$ 776.7k
Ronald Hunt
Independent Director6.8yrsUS$115.45k0%
$ 0
Robert Hopfner
Independent Director4.7yrsUS$115.45k0%
$ 0
Christine Nash
Independent Director2.6yrsUS$108.95k0%
$ 0
Helen Boudreau
Independent Director4.2yrsUS$118.95k0.058%
$ 25.8k
Lucian Iancovici
Independent Director4.5yrsno datano data
Paula Soteropoulos
Independent Director4.1yrsUS$113.95k0.058%
$ 25.8k
Wendy Chung
Independent Director2.3yrsUS$95.00k0%
$ 0
Hui Liu
Independent Director2.6yrsUS$111.45k0%
$ 0

4.1yrs

Average Tenure

56.5yo

Average Age

Experienced Board: RLYB's board of directors are considered experienced (4.1 years average tenure).